Phlow Applauds $15.97 Million U.S. Investment in Domestic Medicine Supply Chain

RegulationIndustry
โดย GlobeNewswire·Read original
Summary · why it matters

Phlow Corp. welcomed a $15.97 million investment from the U.S. Economic Development Administration to launch the End-to-End Commercialization Project, led by Civica, Inc., as part of the Alliance for Building Better Medicine. The project will establish an integrated domestic commercialization pathway connecting domestically sourced key starting materials, active pharmaceutical ingredient manufacturing, finished dose formulation and manufacturing, regulatory approval, and delivery of medicines to patients. It will initially focus on four essential sterile injectable medicines used in emergency, anesthesia, and critical care settings. Phlow, a founding member of the Alliance, will contribute its expertise in domestic API development and manufacturing alongside Civica, Occam Systems, and more than 55 public and private partners. The initiative builds on years of public-private collaboration that have helped establish Virginia as a leading hub for advanced pharmaceutical manufacturing.

Impact on stocks 0

Off-coverage companies 3

Civica, Inc.Private▲ Positive
Demandrelevance

Civica leads the project, securing $15.97M to commercialize domestic medicines, directly boosting its pipeline and market position.

Phlow Corp.Private▲ Positive
Demandrelevance

Phlow, as a founding member, contributes its API expertise and gains from the investment and expanded domestic supply chain.

Occam SystemsPrivate▲ Positive
Demandrelevance

Occam Systems is a partner in the project, benefiting from increased collaboration and potential future contracts.

© 2026 MarketDXNews